All stock lists
Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
Healthcare · Biotechnology
17.03+0.00 (+0.00%)
Insider Score
––Not scored
TBPH Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
TBPH Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 20.73 M | 17.70 M | 45.89 M | 19.99 M | 26.20 M |
| Revenue Growth (YoY) | -20.86 % | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| SG&A Expense | 14.18 M | 17.72 M | 18.52 M | 18.33 M | 18.43 M |
| R&D Expense | 4.71 M | 5.83 M | 7.36 M | 8.11 M | 10.49 M |
| Operating Expenses | 18.89 M | 23.55 M | 25.88 M | 26.45 M | 28.92 M |
| Operating Income | 1.84 M | -5.85 M | 20.01 M | -6.46 M | -2.73 M |
| Pretax Income | -4.79 M | -6.47 M | 73.07 M | -2.89 M | 73.21 M |
| Tax Provision | 1.11 M | -1.54 M | 12.04 M | -6.50 M | 18.37 M |
| Net Income | -5.90 M | -4.93 M | 61.02 M | 3.62 M | 54.84 M |
| EPS (Basic) | -0.11 | -0.10 | 1.20 | 0.07 | 1.09 |
| EPS (Diluted) | -0.11 | -0.10 | 1.15 | 0.07 | 1.08 |
| Shares Outstanding | 51.67 M | 51.28 M | 50.87 M | 50.52 M | 50.18 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.